TCGA-55-6975-01A-11R-1949-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- TGF_BETA_SIGNALING+0.510
- G2M_CHECKPOINT+0.370
- ANDROGEN_RESPONSE+0.340
- MITOTIC_SPINDLE+0.340
- MYC_TARGETS_V1+0.320
- E2F_TARGETS+0.310
- ANGIOGENESIS+0.300
- APICAL_JUNCTION+0.290
- MTORC1_SIGNALING+0.290
Top 10 suppressed
- P53_PATHWAY-0.230
- IL6_JAK_STAT3_SIGNALING-0.200
- BILE_ACID_METABOLISM-0.180
- ALLOGRAFT_REJECTION-0.170
- KRAS_SIGNALING_DN-0.160
- PEROXISOME-0.090
- INFLAMMATORY_RESPONSE-0.070
- INTERFERON_GAMMA_RESPONSE-0.070
- FATTY_ACID_METABOLISM-0.050
- UV_RESPONSE_UP-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1N6-01A-11R-A144-07 | — | C | 0.828 |
| 2 | TCGA-DK-A1A5-01A-11R-A13Y-07 | — | — | 0.819 |
| 3 | SRR17866829 | — | — | 0.813 |
| 4 | BS_7327SDAQ | high-grade glioma | — | 0.801 |
| 5 | TCGA-68-7756-01A-11R-2125-07 | — | cohortSQ1 | 0.796 |
| 6 | C3N-00211 | — | cohortSQ1 | 0.786 |
| 7 | 5282B52E-8573-4FC0-9BED-420AE3D2B096 | — | — | 0.784 |
| 8 | MNG308 | — | — | 0.778 |
| 9 | SJEPD031429_D1.RNA-Seq | EPN | EPN Tumor | 0.777 |
| 10 | BS_23M72ABG | Meningioma | — | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.510 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.340 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.300 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.290 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.290 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| COAGULATION | 0.230 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.230 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.190 | Idelalisib | — uncovered |
| APOPTOSIS | 0.180 | Idelalisib | — uncovered |